{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T10:34:11Z","timestamp":1721644451828},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cempra Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ijantimicag.2017.01.035","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T19:16:02Z","timestamp":1494011762000},"page":"17-22","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections"],"prefix":"10.1016","volume":"50","author":[{"given":"Stephen","family":"Hawser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Keedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0010","first-page":"e9","article-title":"Predictors of failure of noninvasive ventilation in patients with severe community-acquired pneumonia","volume":"540","author":"Carron","year":"2010","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.diagmicrobio.2005.10.007","article-title":"Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals","volume":"54","author":"Davydov","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0020","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/archinte.167.15.1664","article-title":"The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumonia","volume":"167","author":"Fishbane","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.amjmed.2005.06.035","article-title":"Low-risk patients admitted with community-acquired pneumonia","volume":"118","author":"Marrie","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MD.0b013e3180421c16","article-title":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study","volume":"86","author":"Marrie","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0035","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2169\/internalmedicine.44.710","article-title":"Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality","volume":"44","author":"Yoshimoto","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.CCM.0000150265.42067.4C","article-title":"Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10096-007-0307-3","article-title":"Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia","volume":"26","author":"Chokshi","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0060","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/eri.10.35","article-title":"Levofloxacin in the treatment of community-acquired pneumonia","volume":"8","author":"Noreddin","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2017.01.035_bib0065","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/S0924-8579(05)80321-8","article-title":"Value of short-course antimicrobial therapy in community-acquired pneumonia","volume":"26","author":"Blasi","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0070","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1445-5994.2007.01497.x","article-title":"One drug or two? Step-down therapy after i.v. antibiotics for community-acquired pneumonia","volume":"37","author":"Harrington","year":"2007","journal-title":"Intern Med J"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0080","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QCO.0b013e3280555072","article-title":"How long should we treat community-acquired pneumonia?","volume":"20","author":"Scalera","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1183\/09031936.00130909","article-title":"Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia","volume":"36","author":"Aliberti","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0100","author":"Sprenger"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0105","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0110","series-title":"Performance standards for antimicrobial susceptibility testing. Informational Supplement","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0115","author":"Tygacil"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0120","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/AAC.00275-07","article-title":"Update to the multiplex PCR strategy for assignment of mec element types in Staphylococcus aureus","volume":"51","author":"Milheiri\u00e7o","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0125","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1128\/AAC.40.11.2562","article-title":"Detection of erythromycin-resistant determinants by PCR","volume":"40","author":"Sutcliffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.diagmicrobio.2012.08.024","article-title":"Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998\u20132011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ijantimicag.2007.10.022","article-title":"Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT year 5 (2003\u20132004)","volume":"31","author":"Farrell","year":"2008","journal-title":"Int J Antimicrob Agent"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0140","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/AAC.05658-11","article-title":"Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study","volume":"56","author":"Kim","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0145","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3201\/eid1106.050147","article-title":"Hidden epidemic of macrolide-resistant pneumococci","volume":"11","author":"Klugman","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0150","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1179\/joc.2007.19.5.536","article-title":"A case series of macrolide treatment failures in community acquired pneumonia","volume":"19","author":"Iannini","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0160","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/AAC.04568-14","article-title":"Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012","volume":"59","author":"Farrell","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.01.035_bib0165","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2165\/00003495-200262120-00006","article-title":"the ketolides: a critical review","volume":"62","author":"Zhanel","year":"2002","journal-title":"Drugs"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917301425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:08:18Z","timestamp":1569247698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917301425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0924857917301425"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.035","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}